Velocity Clinical Research

Industry / private company


Location: Durham, United States (USA) (US) US

ROR: https://ror.org/04nh35860

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) (2025) Agarwal R, Green JB, Heerspink HJ, Mann JF, McGill JB, Mottl AK, Nangaku M, et al. Journal article Combination effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics (2025) Agarwal R, Green JB, Heerspink HJ, Mann JF, McGill JB, Mottl AK, Rosenstock J, et al. Journal article